Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tivantinib

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

- PMLiVE

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments

- PMLiVE

The oncology market in Canada

Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture

- PMLiVE

Lilly depression drug fails late-stage trials

Will not pursue edivoxetine as an add-on treatment for depression

Roche - Basel

Roche signs $1bn-plus cancer deal with Molecular Partners

Partnership could create new type of drug conjugate similar to ADCs

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

- PMLiVE

Nexavar cleared for thyroid cancer by FDA

Bayer and Onyx win expansion of oncology drug’s use in US

Daiichi Sankyo logo

Daiichi Sankyo says meets targets in AF study

Edoxaban on course to add to next generation anticoagulants to replace warfarin

Roche - Basel

EU backs Roche’s Kadcyla in breast cancer

Green light for Herceptin follow-up

Bayer symbol

EU approval for Bayer’s prostate cancer drug

Xofigo wins marketing authorisation from European Commission

- PMLiVE

Boehringer to help promote genetic biomarker testing

Will support Bonnie J Addario Lung Cancer Foundation

- PMLiVE

Late-stage ovarian cancer

Novel treatment strategies have yielded several promising agents that have reached phase III

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links